Clinical manifestations and quality of life in hidradenitis suppurativa patients: survey of participants from an internet support group

Távora, Isabel; Bissoli, Gabriela Cabral; Miot, Hélio Amante; Schmitt, Juliano Vilaverde

doi:10.1590/abd1806-4841.20197687

Cited by 8 publications

(17 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…QoL assessment scores for patients with HS are often worse than QoL scores for patients with other dermatological conditions, malignant neoplasms, Parkinson's disease and stroke. 4 The results of this study demonstrate that weekly administration of ADA through 124 weeks is safe and effective for treating Japanese patients who are living with moderate to severe HS. Results from the group who switched to a less frequent dosing regimen remained similar in efficacy, safety and QoL outcomes.…”

Section: Discussionmentioning

confidence: 67%

“…Hidradenitis suppurativa (HS) is a difficult to treat, chronic, painful skin disease characterized by deep-seated inflammatory nodules and abscesses, fistula formation and subsequent scarring, which negatively impacts patients' quality of life (QoL). [1][2][3][4] Prevalence of HS in Eastern and Western countries varies. In Eastern countries, HS is 2-3-fold more prevalent in men than in women, with approximately two-thirds of patients having Hurley stage II or III disease and the buttocks, axillae and groin areas being the most commonly affected anatomical locations.…”

Section: Introductionmentioning

confidence: 99%

“…11 HS also negatively effects patients' daily activities and is associated with several comorbidities, including mental health disorders and cellulitis; therefore, early diagnosis and treatment are clinically important. 4,[10][11][12] Adalimumab (ADA; Humira â [AbbVie, North Chicago, IL, USA]) is a monoclonal antibody against tumor necrosis factor (TNF)-a, and is the only medication approved in Japan (at a dose of 40 mg every week), the USA and the EU for the treatment of HS. [13][14][15] In Japan, ADA has been approved to treat rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, HS, juvenile idiopathic arthritis, ulcerative colitis, intestinal Behc ßet's disease, non-infectious intermediate uveitis, posterior uveitis or panuveitis and generalized pustular psoriasis.…”

Section: Introductionmentioning

confidence: 99%

“…Hidradenitis suppurativa (HS) is a difficult to treat, chronic, painful skin disease characterized by deep‐seated inflammatory nodules and abscesses, fistula formation and subsequent scarring, which negatively impacts patients’ quality of life (QoL) 1–4 . Prevalence of HS in Eastern and Western countries varies.…”

Section: Introductionmentioning

confidence: 99%

“…The long‐term impact of HS on patient QoL goes beyond the associated chronic pain that can sometimes be intense and includes increases in health‐care‐related costs 11 . HS also negatively effects patients’ daily activities and is associated with several comorbidities, including mental health disorders and cellulitis; therefore, early diagnosis and treatment are clinically important 4,10–12 . Adalimumab (ADA; Humira ® [AbbVie, North Chicago, IL, USA]) is a monoclonal antibody against tumor necrosis factor (TNF)‐α, and is the only medication approved in Japan (at a dose of 40 mg every week), the USA and the EU for the treatment of HS 13–15…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Long‐term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open‐label phase 3 results

et al. 2020

View full text Add to dashboard Cite

This phase 3, multicenter, open-label single-arm study evaluated adalimumab (ADA) in Japanese patients with moderate to severe hidradenitis suppurativa (HS). Fifteen patients received ADA 160 mg s.c. at week 0, 80 mg at week 2 and 40 mg at week 4 and every week thereafter. At any time after week 52, patients were given the option to receive 80 mg ADA every other week or remain on 40 mg every week. The primary end-point (achievement of HS Clinical Response [HiSCR] at week 24) and results up to week 24 were published previously. Secondary endpoints included total abscess and inflammatory nodule (AN) count, 30% or more and 1 unit or more reduction in Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS30), modified Sartorius score and quality of life (QoL). After 12 weeks of ADA treatment, the achievement rate in HiSCR was 86.7%; HiSCR achievement rate was sustained through week 52 at 66.7%. Improvements at week 12 were also seen in the proportion of patients achieving an AN count of 0-2; NRS30 response rate among the nine patients with a baseline NRS of 3 or more; mean decrease in modified Sartorius score (61.4); and QoL as assessed by Dermatology Life Quality Index and Treatment Satisfaction Questionnaire; these improvements were maintained through 52 weeks. Similar efficacy was observed when patients switched dosing from ADA 40 mg every week to ADA 80 mg every other week. There were no new safety findings with ADA 40 mg weekly dosing during the study, and no differences in safety were found between patients who switched to 80 mg ADA every other week and patients who remained on 40 mg every week. The results of this study indicate that long-term ADA treatment is effective and well tolerated in Japanese patients with moderate to severe HS.

show abstract

Section: Discussionmentioning

confidence: 67%